Drucken

ExpertFORUM Pharmacovigilance 2018

12.11.2018 - 13.11.2018

Your regulatory update about all aspects about drug safety in Europe

Save the date! Your regulatory update in pharmacovigilance with european drug safety experts and a special network event.

Topics

  • IDMP and SPOR: Consequences for pharmacovigilance
  • Data protection, the new EU regulation and initial experiences
  • CMDh RMP work sharing
  • EudraVigilance and signal management
  • Brexit countdown
  • Mergers and acquisitions: A drug safety perspective
  • Inspection readiness - an authority's perspective
  • Liability issues in pharmacovigilance
  • And much more

Aims and objectives

FORUM Institut and the conference chairs are pleased to welcome you to this year's ExpertFORUM Pharmacovigilance.
This conference has become a jour fixe for drug safety departments in the pharmaceutical industry. As always, we will highlight the latest regulatory developments and their implications for the pharmaceutical industry, and provide concrete suggestions for your daily work. We will also provide the latest information on current pharmacovigilance issues.
I look forward to meeting you personally in Frankfurt.

Who should attend

The conference is primarily intended for drug safety managers, local drug safety representatives and QPPVs needing to be informed about current regulatory developments and operational implementation issues.

It is also aimed at senior executives at public authorities and research institutions, and in:

  • Medical Affairs;
  • Regulatory Affairs;
  • Clinical Research; and
  • Quality assurance.

Veranstaltungsort

Le Méridien Parkhotel
Wiesenhüttenplatz 28-38
60329 Frankfurt

Veranstalter

FORUM Institut für Management GmbH

Sträter Rechtsanwälte
Kronprinzenstraße 20
D-53173 Bonn

Fon +49 (0) 228 93454-0
Fax +49 (0) 228 93454-54

mail(at)straeterlawyers.de

Referent

Prof. Burkhard Sträter

Prof. Burkhard Sträter hat die Kanzlei im Jahre 1987 gegründet und konsequent auf die Schwerpunktgebiete konzentriert. Er ist Honorarprofessor an der Universität Bonn und leitet den Studiengang Master of Drug Regulatory Affairs (MDRA), www.dgra.de.

E-Mail: